Early B cell changes predict autoimmunity following combination immune checkpoint blockade

Combination checkpoint blockade (CCB) targeting inhibitory CTLA4 and PD1 receptors holds promise for cancer therapy. Immune-related adverse events (IRAEs) remain a major obstacle for the optimal application of CCB in cancer. Here, we analyzed B cell changes in patients with melanoma following treatm...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:J Clin Invest
Glavni autori: Das, Rituparna, Bar, Noffar, Ferreira, Michelle, Newman, Aaron M., Zhang, Lin, Bailur, Jithendra Kini, Bacchiocchi, Antonella, Kluger, Harriet, Wei, Wei, Halaban, Ruth, Sznol, Mario, Dhodapkar, Madhav V., Dhodapkar, Kavita M.
Format: Artigo
Jezik:Inglês
Izdano: American Society for Clinical Investigation 2018
Teme:
Concise Communication
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5785243/
https://ncbi.nlm.nih.gov/pubmed/29309048
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI96798
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items